Steinberg R A, Russell J L, Murphy C S, Yphantis D A
J Biol Chem. 1987 Feb 25;262(6):2664-71.
Two S49 mouse lymphoma cell variants hemizygous for expression of mutant regulatory (R) subunits of type I cyclic AMP-dependent protein kinase were used to investigate functional consequences of lesions in the putative cAMP-binding sites of R subunit. Kinase activation properties of wild-type and mutant enzymes were compared using cAMP and six site-selective analogs of cAMP. Kinases from both mutant sublines were relatively resistant to cyclic nucleotide-dependent activation, but they were fully activable by at least some effectors. Relative resistances of the mutant kinases varied from about 5-fold for analogs selective for their nonmutated sites to as much as 700-fold for analogs selective for their mutated sites; resistance to cAMP was intermediate. Apparent affinities of wild-type and mutant R subunits for [3H]cAMP were not appreciably different, but competition experiments with site-selective analogs of cAMP suggested that binding of cAMP to mutant R subunits was primarily to their nonmutated sites. Analyses of cooperativity in cyclic nucleotide-dependent activation of mutant kinases, synergism between site I- and site II-selective analogs in activating the mutant enzymes, and dissociation of bound cAMP from mutant R subunits provided additional evidence that the mutations in these strains selectively inactivated single classes of cAMP-binding sites: phenomena attributable in wild-type enzyme to intrachain interactions between sites I and II were always absent or severely diminished in experiments with the mutant enzymes. These results confirm that R subunit sequences implicated in cAMP binding by homology with other cyclic nucleotide-binding proteins actually correspond to functional cAMP-binding sites. Furthermore, occupation of either cAMP-binding site I or II is apparently sufficient for activation of cAMP-dependent protein kinase. The presence of four functional cAMP-binding sites in wild-type kinase enhances the cooperativity and sensitivity of cAMP-mediated activation.
利用两个杂合表达I型环磷酸腺苷(cAMP)依赖性蛋白激酶突变调节(R)亚基的S49小鼠淋巴瘤细胞变体,研究R亚基假定cAMP结合位点损伤的功能后果。使用cAMP和六种cAMP位点选择性类似物比较野生型和突变型酶的激酶激活特性。来自两个突变亚系的激酶对环核苷酸依赖性激活相对耐药,但它们至少可被某些效应物完全激活。突变激酶的相对耐药性因对其未突变位点有选择性的类似物约为5倍,到对其突变位点有选择性的类似物高达700倍不等;对cAMP的耐药性处于中间水平。野生型和突变型R亚基对[3H]cAMP的表观亲和力没有明显差异,但用cAMP位点选择性类似物进行的竞争实验表明,cAMP与突变型R亚基的结合主要是与其未突变位点结合。对突变激酶环核苷酸依赖性激活中的协同性分析、位点I和位点II选择性类似物在激活突变酶中的协同作用以及结合的cAMP从突变型R亚基上的解离,提供了额外证据,表明这些菌株中的突变选择性地使单类cAMP结合位点失活:在野生型酶中归因于位点I和位点II之间链内相互作用的现象,在突变酶实验中总是不存在或严重减弱。这些结果证实,通过与其他环核苷酸结合蛋白的同源性与cAMP结合相关的R亚基序列实际上对应于功能性cAMP结合位点。此外,占据cAMP结合位点I或II中的任何一个显然足以激活cAMP依赖性蛋白激酶。野生型激酶中四个功能性cAMP结合位点的存在增强了cAMP介导激活的协同性和敏感性。